Previous Close | 2.5000 |
Open | 2.5600 |
Bid | 2.4000 x 1100 |
Ask | 2.5500 x 100 |
Day's Range | 2.5022 - 2.7050 |
52 Week Range | 0.9630 - 3.7740 |
Volume | |
Avg. Volume | 44,057 |
Market Cap | 191.576M |
Beta (5Y Monthly) | 3.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.4100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.43 |
PARIS, March 04, 2024 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights02/29/202471,751,20177,686,895 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 4
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the second tranche of €15 million (“Tranche B”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the "Finance Contract"). Tranche B
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommenda